Tadahisa Inoue

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Kiyoaki Ito · 4 shared papers, 2021–2026 · strength 0.95
   • Paper Biliary Drainage During Neoadjuvant Chemotherapy in Pancreatic Cancer: Evidence and Practical Recommendations. DOI 10.3390/cancers18030467↗
   • Paper Endoscopic Ultrasound-Guided Hepaticogastrostomy with Antegrade Stenting Without Dilation Device Application for Malign… DOI 10.1007/s10620-022-07749-5↗
   • Paper Safety and Efficacy of Gemcitabine Plus Nab-Paclitaxel for Metastatic Pancreatic Cancer Patients Undergoing Biliary Ste… DOI 10.1007/s10620-021-07098-9↗
2. Itaru Naitoh · 3 shared papers, 2018–2025 · strength 0.50
   • Paper Balancing efficacy and tolerability in metastatic pancreatic cancer: lessons from the ALPACA trial. DOI 10.21037/hbsn-2025-315↗
   • Paper Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unrese… DOI 10.1097/mpa.0000000000002032↗
   • Paper The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients … DOI 10.1016/j.humpath.2018.01.009↗
3. Masashi Yoneda · 3 shared papers, 2021–2023 · strength 0.45
   • Paper Endoscopic Ultrasound-Guided Hepaticogastrostomy with Antegrade Stenting Without Dilation Device Application for Malign… DOI 10.1007/s10620-022-07749-5↗
   • Paper Safety and Efficacy of Gemcitabine Plus Nab-Paclitaxel for Metastatic Pancreatic Cancer Patients Undergoing Biliary Ste… DOI 10.1007/s10620-021-07098-9↗
   • Paper Gemcitabine plus nab-paclitaxel with initial dose reduction for older patients with advanced pancreatic cancer. DOI 10.1016/j.jgo.2020.06.017↗
4. Mayu Ibusuki · 3 shared papers, 2021–2023 · strength 0.45
   • Paper Endoscopic Ultrasound-Guided Hepaticogastrostomy with Antegrade Stenting Without Dilation Device Application for Malign… DOI 10.1007/s10620-022-07749-5↗
   • Paper Safety and Efficacy of Gemcitabine Plus Nab-Paclitaxel for Metastatic Pancreatic Cancer Patients Undergoing Biliary Ste… DOI 10.1007/s10620-021-07098-9↗
   • Paper Gemcitabine plus nab-paclitaxel with initial dose reduction for older patients with advanced pancreatic cancer. DOI 10.1016/j.jgo.2020.06.017↗
5. Tsuyoshi Sano · 1 shared paper, 2026 · strength 0.36
   • Paper Clinical Implementation Gap of Comprehensive Genomic Profiling in Pancreatic Cancer: A Real-world Study. DOI 10.21873/invivo.14377↗
6. Yasuyuki Fukami · 1 shared paper, 2026 · strength 0.36
   • Paper Clinical Implementation Gap of Comprehensive Genomic Profiling in Pancreatic Cancer: A Real-world Study. DOI 10.21873/invivo.14377↗
7. Masataka Ando · 1 shared paper, 2026 · strength 0.36
   • Paper Clinical Implementation Gap of Comprehensive Genomic Profiling in Pancreatic Cancer: A Real-world Study. DOI 10.21873/invivo.14377↗
8. Michihiro Yoshida · 2 shared papers, 2018–2022 · strength 0.19
   • Paper Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unrese… DOI 10.1097/mpa.0000000000002032↗
   • Paper The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients … DOI 10.1016/j.humpath.2018.01.009↗
9. Akihisa Kato · 2 shared papers, 2018–2022 · strength 0.19
   • Paper Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unrese… DOI 10.1097/mpa.0000000000002032↗
   • Paper The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients … DOI 10.1016/j.humpath.2018.01.009↗
10. Satoru Takahashi · 2 shared papers, 2018–2022 · strength 0.19
    • Paper Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unrese… DOI 10.1097/mpa.0000000000002032↗
    • Paper The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients … DOI 10.1016/j.humpath.2018.01.009↗
11. Hiromi Kataoka · 1 shared paper, 2022 · strength 0.12
    • Paper Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unrese… DOI 10.1097/mpa.0000000000002032↗
12. Yasuki Hori · 1 shared paper, 2022 · strength 0.12
    • Paper Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unrese… DOI 10.1097/mpa.0000000000002032↗
13. Hiroyuki Kato · 1 shared paper, 2022 · strength 0.12
    • Paper Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unrese… DOI 10.1097/mpa.0000000000002032↗
14. Takashi Joh · 1 shared paper, 2018 · strength 0.07
    • Paper The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients … DOI 10.1016/j.humpath.2018.01.009↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.